TREA

Display screen or portion thereof with graphical user interface

Follow

Information

  • Patent Grant
  • D1077824
  • Patent Number
    D1,077,824
  • Date Filed
    Tuesday, February 2, 2021
    5 years ago
  • Date Issued
    Tuesday, June 3, 2025
    8 months ago
  • US Classifications
    Field of Search
    • US
    • D14 485-495
    • CPC
    • G06F3/048
    • G06F3/0481
    • G06F3/04812
    • G06F3/04815
    • G06F3/04817
    • G06F3/0482
    • G06F3/0483
    • G06F3/0484
    • G06F3/04842
    • G06F3/04845
    • G06F3/04847
    • G06F3/0485
    • G06F3/04855
    • G06F3/0486
    • G06F3/04886
    • G06Q30/00
    • G06Q30/02
    • G06Q30/0237
    • G06Q30/0238
    • G06Q30/0239
    • H03J1/00
    • H03J1/0008
    • H03J1/0016
    • H03J1/0025
    • H04N5/00
    • H04N5/08
    • H04N5/14
    • H04N5/222
    • H04N5/225
    • H04N5/232
    • H04N5/23222
    • H04N5/23293
    • H04N5/232933
    • H04N5/232935
    • H04N5/445
    • H04N5/44504
    • H04N5/45
    • H04N21/00
    • H04N21/234
    • H04N21/431
    • H04N21/4312
    • H04N21/4314
    • H04N21/4316
    • H04N21/4532
    • H04N21/4622
    • H04N21/47
    • H04N21/478
    • H04N21/482
    • H04N21/4884
    • H04N21/4888
    • H04N21/4856
    • H04N21/485
    • H04N21/6547
  • International Classifications
    • 1404
    • Term of Grant
      15Years
Information
Abstract
Description


FIG. 1 is a front view of a first embodiment of a display screen or portion thereof with a graphical user interface showing of our new design;



FIG. 2 is a front view of a second embodiment of a display screen or portion thereof with a graphical user interface showing of our new design;



FIG. 3 is a front view of a third embodiment of a display screen or portion thereof with a graphical user interface showing of our new design; and,



FIG. 4 is a front view of a fourth embodiment of a display screen or portion thereof with a graphical user interface showing of our new design.


The dot-dash-dot broken lines illustrate a display screen, which is the environment of the design, and which forms no part of the claimed design. The remaining broken lines illustrate portions of the graphical user interface, and form no part of the claimed design.


Claims
  • The ornamental design for a display screen or portion thereof with a graphical user interface, as shown and described.
US Referenced Citations (13)
Number Name Date Kind
D810111 Garcia Feb 2018 S
D1049146 Shah Oct 2024 S
D1050165 Shah Nov 2024 S
20140287937 So et al. Sep 2014 A1
20170240973 Eltoukhy et al. Aug 2017 A1
20170260590 Eltoukhy Sep 2017 A1
20180300456 Eltoukhy Oct 2018 A1
20180305738 Kennedy Oct 2018 A1
20200308656 Lewin et al. Oct 2020 A1
20210057046 Liu et al. Feb 2021 A1
20240052419 Eltoukhy Feb 2024 A1
20240071628 Eltoukhy Feb 2024 A1
20240153593 Eltoukhy May 2024 A1
Foreign Referenced Citations (4)
Number Date Country
2013190441 Dec 2013 WO
2014039556 Mar 2014 WO
2014043763 Mar 2014 WO
2014165549 Oct 2014 WO
Non-Patent Literature Citations (33)
Entry
Tumor Response Map, posted Aug. 18, 2016 [online], [retrieved Oct. 19, 2023]. Retrieved from internet, https://web.archive.org/web/20210508233308/https://dribbble.com/shots/2907808-Tumor-Response-Map (Year: 2016).
Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome, posted Sep. 19, 2020 [online], [retrieved Oct. 19, 2023]. Retrieved from internet, https://www.sciencedirect.com/science/article/pii/S2666364320 (Year: 2020).
“Guardant Complete”, posted date unavailable [online], [retrieved May 28, 2024]. Retrieved from internet, https://www.guardantcomplete.com/why-guardant/product-portfolio-testing-evidence (Year: 2024).
Chan, K.C.A et al. “Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing” PNAS (2013) 110(47):18761-18768.
European Office Action for EP Application No. 22176398.0, dated Aug. 30, 2023.
Non-final Office Action for U.S. Appl. No. 17/462,906, dated Aug. 16, 2023.
Non-Final Office Action for U.S. Appl. No. 17/699,968 dated Sep. 8, 2023.
Office Action for U.S. Appl. No. 17/822,058 mailed Jun. 27, 2023.
Ding, L. et al. “Clonal evolution in relapsed acute myeloid leukemia revealed by whole-genome sequencing” Nature (2012) 481(7382):506-510.
Forshew, T. et al. “Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA” Sci Transl Med (2012) 4(136) ra68.
Gerlinger, M. et al. “Intratumor heterogeneity and Branched Evolution Revealed by Multiregion Sequencing” New England J Medicine (2012) 366(10):883-892.
Guardant Health Inc. vs. Foundation Medicine GmbH regarding EP3240911B1, Statement of Defense dated Nov. 8, 2021.
Brocks, D. et al. “Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer” Cell Rep. Aug. 7, 2014;8(3):798-806.doi: 10.1016/j.celrep.2014.06.053. Epub Jul. 24, 2014.
Final Office Action for U.S. Appl. No. 17/699,968, dated Dec. 7, 2022.
Kivioja, T., et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. Nov. 20, 2011;9(1):72-4. doi: 10.1038/nmeth. 1778.
Kivioja, T., et al. Counting absolute numbers of molecules using unique molecular identifiers. Nat Methods. Nov. 20, 2011;9(1):72-4. doi: 10.1038/nmeth. 1778. Supplementary Material.
Pan, H. et al. “Epigenomic evolution in diffuse large B-cell lymphomas” Blood (2013) 122(21):634.
Sharma, S.V. et al. “A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations” Cell (2010) 141(1):69-80.
Stefansson, O.A. et al. “Epigenetic Modifications in Breast Cancer and Their Role in Personalized Medicine” Am J Pathology (2013) 183(4):1052-1063.
Final Office Action in U.S. Appl. No. 15/431,395, dated Apr. 28, 2023.
Office Action for U.S. Appl. No. 17/822,058, dated Mar. 10, 2023.
Dingli, D. et al. “(A)Symmetric Stem Cell Replication and Cancer” PLoS Comp Biology (2007) 3(3):e53 482-487.
Ekundayo, B. et al. “Origins of DNA replication” PLoS Genetics (2019) 15(9):e108320, 1-20.
Final Office Action for U.S. Appl. No. 17/462,906, dated Mar. 13, 2024.
Final Office Action for U.S. Appl. No. 17/822,058 dated Apr. 9, 2024.
Final Office Action in U.S. Appl. No. 17/822,058, mailed Sep. 28, 2023.
Office Action for U.S. Appl. No. 17/818,944 dated Dec. 7, 2023.
Pinkel, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. Oct. 1998;20(2):207-11.
Dileep, V. et al. “Single-cell replication profiling to measure stochastic variation in mammalian replication timing” Nature Com (2018) 9:427.
Final Office Action for U.S. Appl. No. 17/818,944 dated Sep. 25, 2024.
Liu, B. et al. “Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges” Oncotarget (2013) 4(11):1868-1881.
Luo, H. et al. “Genome-wide estimation of firing efficiencies of origins of DNA replication from time-course copy number variation data” BMC Bioinformatics (2010) 11:247 (15 pages).
Office Action for U.S. Appl. No. 15/431,395 mailed Jul. 19, 2024.
Continuations (2)
Number Date Country
Parent 15431395 Feb 2017 US
Child 29768979 US
Parent PCT/US2015/067717 Dec 2015 WO
Child 15431395 US